Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis
Iznardo, Helena (Institut de Recerca Sant Pau)
Roé Crespo, Esther (Institut de Recerca Sant Pau)
Serra Baldrich, Esther (Institut de Recerca Sant Pau)
Puig Sanz, Lluís (Institut de Recerca Sant Pau)
Universitat Autònoma de Barcelona

Date:	2023
Abstract:	Abrocitinib is a JAK1 selective inhibitor recently approved for the treatment of moderate-to-severe atopic dermatitis in adults. It has demonstrated efficacy and safety in several clinical trials, both in children and adults, in monotherapy, and compared with dupilumab. The expected EASI-75 response rate estimates at week 12 are 62. 9% (95% CrI 42. 5-79. 9%) for abrocitinib 200 mg and 43. 0% (95% CrI 24. 8-64. 0%) for abrocitinib 100 mg. Abrocitinib has shown a faster effect than dupilumab as regards early alleviation of itch. Because of the incomplete target selectivity of JAK inhibitors, when abrocitinib treatment is considered, laboratory screening is necessary, latent tuberculosis must be screened for, active infections are a contraindication, and special caution must be exerted in treating elderly patients and those predisposed to thromboembolic events. Even though recent meta-analyses of clinical trials have not shown that atopic dermatitis, or its treatment with JAK inhibitors or dupilumab, modify the risk of deep venous thrombosis or pulmonary embolism, long-term follow-up studies will better define the safety profile of abrocitinib.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article de revisió ; recerca ; Versió publicada
Subject:	Abrocitinib ; Jak inhibitor ; JAK1 ; Atopic dermatitis
Published in:	Pharmaceutics, Vol. 15 (january 2023) , ISSN 1999-4923

DOI: 10.3390/pharmaceutics15020385
PMID: 36839707

16 p, 539.9 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles